SCHEMBL10145197

SCHEMBL10145197

CCCN(C(=O)COC(C)=O)C(C)C

nearest known ligand 0.41

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
LMNA P02545 2/20 0.41
HSD17B10 Q99714 1/20 0.41
TSHR P16473 2/20 0.35
FAAH O00519 1/20 0.35
EPHX2 P34913 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.33
POLB P06746 2/20 0.32
PTPN1 P18031 1/20 0.31
KMT2A Q03164 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12919894 0.81 EPHX2 (0.36) ALDH1A1EPHX2KMT2A
SCHEMBL28125779 0.76 ALDH1A1 (0.48) ALDH1A1LMNAHSD17B10TSHRFAAH
SCHEMBL21336736 0.76 ALDH1A1 (0.46) ALDH1A1LMNAHSD17B10TSHRPOLB
SCHEMBL9009588 0.76 EPHX2 (0.39) ALDH1A1TSHREPHX2KMT2ASMN1; SMN2
SCHEMBL11088105 0.75 ALDH1A1 (0.34) ALDH1A1LMNAHSD17B10TSHRL3MBTL1
SCHEMBL18125067 0.75 ALDH1A1 (0.40) ALDH1A1LMNAHSD17B10EPHX2L3MBTL1
SCHEMBL15368915 0.75 ALDH1A1 (0.46) ALDH1A1LMNAHSD17B10TSHRFAAH
SCHEMBL12648593 0.74 EPHX2 (0.45) ALDH1A1TSHREPHX2KMT2A
SCHEMBL497808 0.73 CA12 (0.36) ALDH1A1TSHREPHX2KMT2A
SCHEMBL10106484 0.72 EPHX2 (0.37) ALDH1A1TSHREPHX2L3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8962667-B2 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases Microdose Therapeutix, Inc. (US) 2015-02-24 US disclosed
US-20140363395-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES MICRODOSE THERAPEUTX INC (US) 2014-12-11 US disclosed
US-8846735-B2 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases MICRODOSE THERAPEUTX, INC. (US) 2014-09-30 US disclosed
US-20140072532-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES MICRODOSE THERAPEUTX, INC. (US) 2014-03-13 US disclosed
US-8575205-B2 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases MICRODOSE THERAPEUTX, INC. (US) 2013-11-05 US disclosed
US-20120183498-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES NITZ THEODORE J (US) 2012-07-19 US disclosed
US-8202896-B2 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases MICRODOSE THERAPEUTX, INC. (US) 2012-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140072532-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES TTPA, HAVCR2, ZC3HAV1 ALDH1A1 3354/4885LMNA 254/4885HSD17B10 1959/4885
US-20140363395-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES TTPA, HAVCR2, ZC3HAV1 ALDH1A1 3354/4885LMNA 254/4885HSD17B10 1959/4885
US-20120183498-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES TTPA, HAVCR2, ZC3HAV1 ALDH1A1 3354/4885LMNA 254/4885HSD17B10 1959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.